Skip to content
2000
Volume 19, Issue 2
  • ISSN: 2772-2708
  • E-ISSN: 2772-2716

Abstract

Acanthosis Nigricans is a dermatological condition characterized by hyperpigmented velvet plaques that can be observed in flexural areas such as the neck, axilla, and groin. AN is frequently associated with insulin resistance and obesity, however, it can also appear in non-obese people and as a paraneoplastic disease. Its prevalence varies across different populations, with higher rates observed in individuals with obesity, diabetes, and certain genetic syndromes. Classification of AN can be based on underlying etiology, distinguishing primary and secondary forms. Pathogenesis is the complex interplay of genetic, hormonal, and environmental factors, with insulin resistance playing a central role. Diagnosis relies on clinical evaluation of characteristics of skin changes, often requiring further investigation for underlying systemic disease. Topical therapies involve keratolytic agents, retinoids, and alpha hydroxyl acids to improve the cosmesis and reduce the plaque's thickness. Treatment strategies address underlying conditions by emphasizing lifestyle modifications and in some cases, pharmacological interventions.

This review aims to comprehensively examine the pathogenesis, clinical manifestation, and management of acanthosis nigricans.

AN is closely linked to insulin resistance, characterized by impaired cellular response to insulin, leading to compensatory hyperinsulinemia. Recognizing AN’s clinical presentation is paramount for early diagnosis and appropriate management.

Acanthosis Nigricans is a skin condition characterized by dark, thickened patches of skin, typically occurring in skin folds and creases. It can be a sign of an underlying health issue such as insulin resistance, obesity, hormonal disorders, or certain medications. Proper diagnosis and management of the underlying conditions are crucial. Treatment may involve addressing the underlying causes, lifestyle changes, and topical medications to improve the appearance of the skin. Regular monitoring and follow-up with a health care professional are essential for optimal management and to prevent complications.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raiad/10.2174/0127722708314530240919054410
2025-10-03
2025-10-03

  • From This Site

    /content/journals/raiad/10.2174/0127722708314530240919054410
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BurkeJ.P. HaleD.E. HazudaH.P. SternM.P. A quantitative scale of acanthosis nigricans.Diabetes Care199922101655165910.2337/diacare.22.10.165510526730
     [Google Scholar]
  2. OzluE. UzuncakmakT.K. TakırM. AkdenizN. KaradagA.S. Comparison of cutaneous manifestations in diabetic and nondiabetic obese patients: A prospective, controlled study.North. Clin. Istanb.20185211411930374476
     [Google Scholar]
  3. SmidC.J. ModaffP. AladeA. LegareJ.M. PauliR.M. Acanthosis nigricans in achondroplasia.Am. J. Med. Genet. A.2018176122630263610.1002/ajmg.a.4050630380187
     [Google Scholar]
  4. HigginsS.P. FreemarkM. ProseN.S. Acanthosis Nigricans: A practical approach to evaluation and management.Dermatol. Online J.2008149210.5070/D37MF6G29019061584
     [Google Scholar]
  5. PopaM.L. PopaA.C. TanaseC. Gheorghisan-GalateanuA.A. Acanthosis nigricans: To be or not to be afraid.Oncol. Lett.20191754133413830944606
     [Google Scholar]
  6. VarthakaviP.K. WaingankarA. PatelK.L. WadhwaS.L. KhopkarU. SenguptaR.A. MerchantP.C. MehtaliaS.D. NihalaniK.D. Acanthosis nigricans: a dermatologic marker of metabolic disease.Venereology and Leprology.2002682677217656880
     [Google Scholar]
  7. González-SaldivarG. Rodríguez-GutiérrezR. Ocampo-CandianiJ. González-GonzálezJ.G. Gómez-FloresM. Skin manifestations of insulin resistance: from a biochemical stance to a clinical diagnosis and management.Dermatol. Ther. (Heidelb.)201771375110.1007/s13555‑016‑0160‑327921251
     [Google Scholar]
  8. NgH.Y. Acanthosis nigricans in obese adolescents: prevalence, impact, and management challenges.Adolesc. Health Med. Ther.2016811010.2147/AHMT.S10339628031729
     [Google Scholar]
  9. KanwarA.J. SawatkarG.U. DograS. BhadadaS.K. Acanthosis nigricans--An uncommon cutaneous adverse effect of a common medication: Report of two cases.Indian J. Dermatol. Venereol. Leprol.201379455310.4103/0378‑6323.11311223760338
     [Google Scholar]
  10. YuQ. LiX.L. JiG. WangY. GongY. XuH. ShiY.L. Malignant acanthosis nigricans: an early diagnostic clue for gastric adenocarcinoma.World J. Surg. Oncol.201715120810.1186/s12957‑017‑1274‑529178944
     [Google Scholar]
  11. PhiskeM. An approach to acanthosis nigricans.Indian Dermatol. Online J.20145323924910.4103/2229‑5178.13776525165638
     [Google Scholar]
  12. BishnoiA. ParsadD. Velvety hyperpigmentation on hands and feet of a young girl: Acral acanthosis nigricans.J. Cutan. Med. Surg.201822332310.1177/120347541773628229865956
     [Google Scholar]
  13. KuraM. SanghaviS. Acral acanthosis nigricans in a case of scleroderma.Indian J. Dermatol.201560442310.4103/0019‑5154.16054026288450
     [Google Scholar]
  14. CamaA. de la Luz SierraM. KadowakiT. KadowakiH. QuonM.J. RüdigerH.W. DreyerM. TaylorS.I. Two mutant alleles of the insulin receptor gene in a family with a genetic form of insulin resistance: a 10 base pair deletion in exon 1 and a mutation substituting serine for asparagine-462.Hum. Genet.199595217418210.1007/BF002093977860063
     [Google Scholar]
  15. KimH.N. FessehaB. AnzaldiL. TsaoA. GaliatsatosP. SidhayeA. Antibody-mediated extreme insulin resistance: a report of three cases.Am. J. Med.2018131110210610.1016/j.amjmed.2017.08.00428822702
     [Google Scholar]
  16. MiquelJ. Hadj-RabiaS. BoddaertN. LascellesK. Bahi-BuissonN. Atypical presentation of neuropsychiatric lupus with acanthosis nigricans.Pediatr. Neurol.201247429129410.1016/j.pediatrneurol.2012.06.00522964444
     [Google Scholar]
  17. KondoY. UmegakiN. TeraoM. MurotaH. KimuraT. KatayamaI. A case of generalized acanthosis nigricans with positive lupus erythematosus-related autoantibodies and antimicrosomal antibody: autoimmune acanthosis nigricans?Case Rep. Dermatol.201241859110.1159/00033775122649336
     [Google Scholar]
  18. Imperato-McGinleyJ. PetersonR.E. SturlaE. DawoodY. BarR.S. Primary amenorrhea associated with hirsutism, acanthosis nigricans, dermoid cysts of the ovaries and a new type of insulin resistance.Am. J. Med.197865238939510.1016/0002‑9343(78)90838‑0686026
     [Google Scholar]
  19. Hermanns-LêT. ScheenA. PiérardG.E. Acanthosis nigricans associated with insulin resistance : pathophysiology and management.Am. J. Clin. Dermatol.20045319920310.2165/00128071‑200405030‑0000815186199
     [Google Scholar]
  20. BradyMF RawlaP Acanthosis nigricans.In: StatPearlsTreasure Island (FL): StatPearls Publishing2024
     [Google Scholar]
  21. TorleyD. BellusG.A. MunroC.S. Genes, growth factors and acanthosis nigricans.Br. J. Dermatol.200214761096110110.1046/j.1365‑2133.2002.05150.x12452857
     [Google Scholar]
  22. NeaguM. CaruntuC. ConstantinC. BodaD. ZuracS. SpandidosD.A. TsatsakisA.M. Chemically induced skin carcinogenesis: Updates in experimental models (Review).Oncol. Rep.20163552516252810.3892/or.2016.468326986013
     [Google Scholar]
  23. RudmanS.M. PhilpottM.P. ThomasG.A. KealeyT. The role of IGF-I in human skin and its appendages: morphogen as well as mitogen?J. Invest. Dermatol.1997109677077710.1111/1523‑1747.ep123409349406819
     [Google Scholar]
  24. JeongK.H. OhS.J. ChonS. LeeM.H. Resistance Syndrome: A Case Report Generalized Acanthosis Nigricans Related to Type B Insulin From the Department of Dermatology and the Department of Internal Medicine, College of Medicine, Kyunghee University, Seoul, Korea.Cutis201086629921284281
     [Google Scholar]
  25. NapolitanoM. MegnaM. MonfrecolaG. Insulin resistance and skin diseases.Sci. World J.20152015147935410.1155/2015/47935425977937
     [Google Scholar]
  26. BlombergM. JeppesenE.M. SkovbyF. BenfeldtE. FGFR3 mutations and the skin: report of a patient with a FGFR3 gene mutation, acanthosis nigricans, hypochondroplasia and hyperinsulinemia and review of the literature.Dermatology2010220429730510.1159/00029757520453470
     [Google Scholar]
  27. MirA. WuT. OrlowS.J. Cutaneous features of Crouzon syndrome with acanthosis nigricans.JAMA Dermatol.2013149673774110.1001/jamadermatol.2013.301923571469
     [Google Scholar]
  28. LaneS.W. ManoharanS. MolleeP.N. Palifermin-induced acanthosis nigricans.Intern. Med. J.200737641741810.1111/j.1445‑5994.2007.01340.x17535389
     [Google Scholar]
  29. KrawczykM. Mykała-CieślaJ. Kołodziej-JaskułaA. Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature.Polish Archives of Internal Medicine2009119318018310.20452/pamw.64219514649
     [Google Scholar]
  30. JamesWD ElstonD BergerT Andrew's diseases of the skin. In: Clinical dermatologyElsevier2011
     [Google Scholar]
  31. BurnsT. BreathnachS.M. CoxN. GriffithsC. Rook’s textbook of dermatology.John Wiley & Sons2008
     [Google Scholar]
  32. PavithranK. KarunakaranM. PalitA. Disorders of keratinization.IADVL Textbook of Dermatology.3rd ed ValiaR.G. AmeetR.V. MumbaiBhalani Publishing House200810091011
     [Google Scholar]
  33. DevpuraS. PattamadilokB. SyedZ.U. VemulapalliP. HendersonM. RehseS.J. HamzaviI. LimH.W. NaikR. Critical comparison of diffuse reflectance spectroscopy and colorimetry as dermatological diagnostic tools for acanthosis nigricans: a chemometric approach.Biomed. Opt. Express2011261664167310.1364/BOE.2.00166421698027
     [Google Scholar]
  34. GuptaA.K. BluhmR. CooperE.A. SummerbellR.C. BatraR. Seborrheic dermatitis.Dermatol. Clin.200321340141210.1016/S0733‑8635(03)00028‑712956195
     [Google Scholar]
  35. HayR.J. Tinea capitis: current status.Mycopathologia20171821-2879310.1007/s11046‑016‑0058‑827599708
     [Google Scholar]
  36. DunnC. ApplebaumD.S. DaoH.Jr Widespread hyperpigmented rash present for 1 year.JAAD Case Rep.20184874374510.1016/j.jdcr.2018.04.01230225330
     [Google Scholar]
  37. ErythrasmaT-N.I. AgoEmergencias.2018304283
     [Google Scholar]
  38. Raesi VananiA. MahdaviniaM. KalantariH. KhoshnoodS. ShiraniM. Antifungal effect of the effect of Securigera securidaca L. vaginal gel on Candida species. Curr. Med. Mycol.201953313510.18502/cmm.5.3.174431850394
     [Google Scholar]
  39. SavvidouS. Pellagra: a non-eradicated old disease.Clin. Pract.20144163710.4081/cp.2014.63724847436
     [Google Scholar]
  40. JaffarH. ShakirZ. KumarG. AliI.F. Ichthyosis vulgaris: An updated review.Skin Health Dis.202331e18710.1002/ski2.18736751330
     [Google Scholar]
  41. NicholsonCL DaveluyS Epidermal nevus syndromes.In: StatPearlsTreasure Island (FL): StatPearls Publishing2024
     [Google Scholar]
  42. LuceroR HorowitzD. Granular parakeratosis.In: StatPearlsTreasure Island (FL): StatPearls Publishing2024
     [Google Scholar]
  43. NgH.Y. YoungJ.H. HuenK.F. ChanL.T. Acanthosis nigricans in obese Chinese children.Hong Kong Med. J.201420429029624762331
     [Google Scholar]
  44. BrickmanW.J. BinnsH.J. JovanovicB.D. KoleskyS. ManciniA.J. MetzgerB.E. Acanthosis nigricans: a common finding in overweight youth.Pediatr. Dermatol.200724660160610.1111/j.1525‑1470.2007.00547.x18035980
     [Google Scholar]
  45. OttoD.E. WangX. GarzaV. FuentesL.A. RodriguezM.C. SullivanP. Increasing body mass index, blood pressure, and Acanthosis Nigricans abnormalities in school-age children.J. Sch. Nurs.201329644245110.1177/105984051348318023553623
     [Google Scholar]
  46. Nsiah-KumiP.A. BealsJ. LasleyS. WhitingM. BrushbreakerC. EricksonJ. QiuF. YuF. CanarisG. LarsenJ.L. Body mass index percentile more sensitive than acanthosis nigricans for screening Native American children for diabetes risk.J. Natl. Med. Assoc.20101021094494910.1016/S0027‑9684(15)30714‑821053710
     [Google Scholar]
  47. BergerB.J. GrossP.R. Another use for tretinoin--pseudoacanthosis nigricans.Arch. Dermatol.1973108113313410.1001/archderm.1973.016202200870294716734
     [Google Scholar]
  48. DarmstadtG.L. YokelB.K. HornT.D. Treatment of acanthosis nigricans with tretinoin.Arch. Dermatol.199112781139114010.1001/archderm.1991.016800700390031863071
     [Google Scholar]
  49. AdigunC.G. PandyaA.G. Improvement of idiopathic acanthosis nigricans with a triple combination depigmenting cream.J. Eur. Acad. Dermatol. Venereol.200923448648710.1111/j.1468‑3083.2008.02931.x18721216
     [Google Scholar]
  50. SchwartzR.A. Efficacy of topical 0.1% adapalene gel for use in the treatment of childhood acanthosis nigricans: a pilot study.Dermatol. Ther.201528426610.1111/dth.1222425817595
     [Google Scholar]
  51. GregoriouS. AnyfandakisV. KontoleonP. ChristofidouE. RigopoulosD. KontochristopoulosG. Acanthosis nigricans associated with primary hypogonadism: Successful treatment with topical calcipotriol.J. Dermatolog. Treat.200819637337510.1080/0954663080205050618608738
     [Google Scholar]
  52. ZayedA. SobhiR.M. Abdel HalimD.M. Using trichloroacetic acid in the treatment of acanthosis nigricans: a pilot study.J. Dermatolog. Treat.201425322322510.3109/09546634.2012.67419422494198
     [Google Scholar]
  53. KatzR.A. Treatment of acanthosis nigricans with oral isotretinoin.Arch. Dermatol.1980116111011110.1001/archderm.1980.016402501120277352756
     [Google Scholar]
  54. Özdemi˙rM. ToyH. Mevli˙toğluİ. Demi˙rkesenC. Generalized idiopathic acanthosis nigricans treated with acitretin.J. Dermatolog. Treat.2006171545610.1080/0954663050049728016511962
     [Google Scholar]
  55. Bellot-RojasP. Posadas-SanchezR. Caracas-PortillaN. Zamora-GonzalezJ. Cardoso-SaldañaG. Jurado-SantacruzF. Posadas-RomeroC. Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study.J. Drugs Dermatol.20065988488917039655
     [Google Scholar]
  56. RomoA. BenavidesS. Treatment options in insulin resistance obesity-related acanthosis nigricans.Ann. Pharmacother.2008427-81090109410.1345/aph.1K44618492785
     [Google Scholar]
  57. SherertzE.F. Improved acanthosis nigricans with lipodystrophic diabetes during dietary fish oil supplementation.Arch. Dermatol.198812471094109610.1001/archderm.1988.016700700820263389852
     [Google Scholar]
  58. CoatesP. ShuttleworthD. ReesA. Resolution of nicotinic acid-induced acanthosis nigricans by substitution of an analogue (acipimox) in a patient with type V hyperlipidaemia.Br. J. Dermatol.1992126441241410.1111/j.1365‑2133.1992.tb00692.x1571266
     [Google Scholar]
  59. PatelN.U. RoachC. AliniaH. HuangW. FeldmanS. Current treatment options for acanthosis nigricans.Clin. Cosmet. Investig. Dermatol.20181140741310.2147/CCID.S13752730122971
     [Google Scholar]
  60. GrecoMJ BhuttaBS Seborrheic keratosis.In: StatPearlsTreasure Island (FL): StatPearls Publishing2024
     [Google Scholar]
  61. RohN.K. HahnH.J. LeeY.W. ChoeY.B. AhnK.J. Clinical and histopathological investigation of seborrheic keratosis.Ann. Dermatol.201628215215810.5021/ad.2016.28.2.15227081260
     [Google Scholar]
  62. PrabhuD. DaweR.S. MpondaK. Pellagra a review exploring causes and mechanisms, including isoniazid-induced pellagra.Photodermatol. Photoimmunol. Photomed.20213729910410.1111/phpp.1265933471377
     [Google Scholar]
  63. Ben GhorbelI. LitaiemN. ChellyI. HoumanH. Pellagra in a patient with primary Sjögren's syndrome.BMJ Case Rep.20142014bcr2014204339
     [Google Scholar]
  64. PatelP. MalikK. KhachemouneA. Sebaceus and Becker’s nevus: overview of their presentation, pathogenesis, associations, and treatment.Am. J. Clin. Dermatol.201516319720410.1007/s40257‑015‑0123‑y25782676
     [Google Scholar]
/content/journals/raiad/10.2174/0127722708314530240919054410
Loading
A Comprehensive Review of Acanthosis Nigricans: Pathogenesis, Clinical manifestation and Management
Rec Adv Inflamm Allergy Drug Discov 19, 135 (2025); https://doi.org/10.2174/0127722708314530240919054410
/content/journals/raiad/10.2174/0127722708314530240919054410
/content/journals/raiad/10.2174/0127722708314530240919054410
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Acanthosis nigricans; acanthosis nigricans; epidemiology; etiology; pathophysiology; topical therapies

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test